Table 3.
Maternal Treatment, Pregnancy, and Infant Outcomes
| Study Outcomes | No. (%) |
|---|---|
| Maternal MDR/RR-tuberculosis treatment outcomes (n = 108) | |
| Favorable treatment outcomes | 72 (67%) |
| Cured | 58 (54%) |
| Treatment completion | 14 (13%) |
| Unfavorable treatment outcomes | 36 (33%) |
| Died | 8 (7%) |
| Treatment failed | 3 (3%) |
| Lost to follow-up | 25 (23%) |
| Pregnancy outcomes (n = 108 women pregnant with n = 109 fetuses, including a set of twins) | |
| Newborn characteristics | |
| Live births | 99 (91%) |
| Gestational age at delivery: weeks, mean; SDa | 37.76; SD 3.10 |
| Birth weight, grams, median [IQR]b | 2800 [2430–3200] |
| Fetal and neonatal deaths | 10 (9%) |
| Stillbirth | 6 (6%) |
| Miscarriagec | 3 (3%) |
| Termination of pregnancy | 1 (1%) |
| Favorable pregnancy outcomes (out of 109 fetuses) | 57 (52%) |
| ≥37 weeksa | 71 (72%) |
| Birthweight ≥2500 gb | 61 (65%) |
| Unfavorable pregnancy outcomes (out of 109 fetuses) | 52 (48%) |
| Fetal and neonatal deaths | 10 (9%) |
| Preterm <37 weeksa | 28 (28%) |
| Low birth weight <2500 gb | 33 (35%) |
| Infant outcomes (n = 109) | |
| No infant outcomes at 12 months (n = 23) | |
| Fetal and neonatal deaths | 10 (9%) |
| Lost to follow-up after birth | 13 (12%) |
| Infant outcomes at 12 months (n = 86) | |
| Favorable infant outcomes | 72 (84%) |
| Thriving normally | 73 (85%) |
| Normal development | 77 (89%) |
| Unfavorable infant outcomes | 14 (16%) |
| Failure to thrive | 9 (10%) |
| Delayed development | 5 (6%) |
| Early neonatal death | 1 (1%) |
| Infant death | 1 (1%) |
| Diagnosed with tuberculosis disease in the 1st year of life | 2 (2%) |
Abbreviations: IQR, interquartile range; MDR/RR, multidrug/rifampicin-resistant.
aLive births only (n = 99).
bLive births only and missing data for 5 neonates (n = 94).
cOne miscarriage was a set of twins.